Predicted protein targets (top 4)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PDE4B | Q07343 | 2/20 | 0.33 |
| ▸ | PDE3A | Q14432 | 2/20 | 0.33 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.33 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL2170274 | 0.76 | PTGS2 (0.35) | PDE4BPDE3AALDH1A1 | |
| SCHEMBL27217735 | 0.74 | ADORA2A (0.39) | KDM4EALDH1A1 | |
| SCHEMBL19747597 | 0.72 | GABRA1 (0.30) | — | |
| SCHEMBL543166 | 0.69 | HSD17B10 (0.36) | KDM4EALDH1A1 | |
| SCHEMBL2171161 | 0.68 | DHFR (0.44) | KDM4EALDH1A1 | |
| SCHEMBL2486926 | 0.68 | KDM4E (0.37) | KDM4EALDH1A1 | |
| SCHEMBL19748477 | 0.66 | NT5E (0.30) | — | |
| SCHEMBL30052564 | 0.65 | KDM4E (0.40) | KDM4EALDH1A1 | |
| SCHEMBL14630035 | 0.65 | KDM4E (0.40) | KDM4EALDH1A1 | |
| SCHEMBL20085817 | 0.62 | KDM4E (0.33) | KDM4EALDH1A1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 11 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20240158394-A1 | NEK7 INHIBITORS | Halia Therapeutics, Inc. | 2024-05-16 | — | — | US | disclosed |
| WO-2024059200-A1 | NEK7 INHIBITORS | Halia Therapeutics, Inc. (US) | 2024-03-21 | — | — | WO | disclosed |
| US-20110224250-A1 | ISOQUINOLINE DERIVATIVE, AND PDE INHIBITOR COMPRISING SAME AS ACTIVE INGREDIENT | KYORIN PHARMACEUTICAL CO., LTD. (JP) | 2011-09-15 | — | — | US | disclosed |
| US-20110224250-A1 | ISOQUINOLINE DERIVATIVE, AND PDE INHIBITOR COMPRISING SAME AS ACTIVE INGREDIENT | KYORIN PHARMACEUTICAL CO., LTD. (JP) | 2011-09-15 | — | — | US | disclosed |
| US-20110224250-A1 | ISOQUINOLINE DERIVATIVE, AND PDE INHIBITOR COMPRISING SAME AS ACTIVE INGREDIENT | KYORIN PHARMACEUTICAL CO., LTD. (JP) | 2011-09-15 | — | — | US | disclosed |
| EP-2351748-A1 | ISOQUINOLINE DERIVATIVE, AND PDE INHIBITOR COMPRISING SAME AS ACTIVE INGREDIENT | Kyorin Pharmaceutical Co., Ltd. (JP) | 2011-08-03 | — | — | EP | disclosed |
| EP-2348018-A1 | HETEROCYCLIC BIARYL DERIVATIVE, AND PDE INHIBITOR COMPRISING SAME AS ACTIVE INGREDIENT | Kyorin Pharmaceutical Co., Ltd. (JP) | 2011-07-27 | — | — | EP | disclosed |
| US-20110178041-A1 | HETEROCYCLIC BIARYL DERIVATIVE AND PDE INHIBITOR COMPRISING SAME AS ACTIVE INGREDIENT | KYORIN PHARMACEUTICAL CO., LTD. (JP) | 2011-07-21 | — | — | US | disclosed |
| US-20110178041-A1 | HETEROCYCLIC BIARYL DERIVATIVE AND PDE INHIBITOR COMPRISING SAME AS ACTIVE INGREDIENT | KYORIN PHARMACEUTICAL CO., LTD. (JP) | 2011-07-21 | — | — | US | disclosed |
| US-20110178041-A1 | HETEROCYCLIC BIARYL DERIVATIVE AND PDE INHIBITOR COMPRISING SAME AS ACTIVE INGREDIENT | KYORIN PHARMACEUTICAL CO., LTD. (JP) | 2011-07-21 | — | — | US | disclosed |
| WO-2010035745-A1 | HETEROCYCLIC BIARYL DERIVATIVE, AND PDE INHIBITOR COMPRISING SAME AS ACTIVE INGREDIENT | 杏林製薬株式会社 (JP) | 2010-04-01 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20110178041-A1 | HETEROCYCLIC BIARYL DERIVATIVE AND PDE INHIBITOR COMPRISING SAME AS ACTIVE INGREDIENT | PDE3A, PDE2A, PDE3B | PDE4B 6/4885PDE3A 1/4885KDM4E 1522/4885 |
| US-20240158394-A1 | NEK7 INHIBITORS | NEK7, NEK5, NEK1 | PDE4B 3227/4885PDE3A 3873/4885KDM4E 3421/4885 |
| US-20110224250-A1 | ISOQUINOLINE DERIVATIVE, AND PDE INHIBITOR COMPRISING SAME AS ACTIVE INGREDIENT | PDE5A, PDE2A, PDE3A | PDE4B 9/4885PDE3A 3/4885KDM4E 1184/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.